earnings
confidence high
sentiment neutral
materiality 0.75
Outset Medical Q2 revenue $25.1M flat; FDA clears Tablo for home use; FY22 guidance $105-110M
Outset Medical, Inc.
2022-Q2 EPS reported
-$1.69
revenue$55,607,000
- Q2 revenue $25.1M flat YoY; net loss ($43.8M) vs ($30.2M); GAAP EPS ($0.92).
- FDA cleared 510(k) for Tablo home use; shipments resumed after voluntary hold.
- FY 2022 guidance: revenue $105M-$110M (2-7% growth) citing staffing & inflation pressures.
- Gross margin improved to 15.1% from 4.2% YoY, but operating expenses rose to $47.5M vs $31.0M.
- Cash $295.4M as of June 30; non-GAAP net loss per share ($0.77).